BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 55 resultados LastUpdate Última actualización 29/09/2020 [21:56:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 3 nextPage   por página


DIAGNOSIS OF CROHN'S DlSEASE AND ULCERATIVE COLITIS

NºPublicación: US2020300866A1 24/09/2020

Solicitante:

FLORA INNOVATION AB [SE]

WO_2019074432_PA

Resumen de: US2020300866A1

The present invention relates to a method for determining if a subject suffers from Crohn's disease or from ulcerative colitis, wherein the method comprises the steps of determining if the subject suffers from inflammatory bowel disease and determining proportion of B-cells which are CD27+ in a sample from the subject. The method may further comprise determining the proportion of CD8+ T-cells which are HLA-DR+ in a sample from the subject. The present invention also relates to biomarkers for use as a marker in the diagnosis of inflammatory bowel disease, Crohn's disease ulcerative colitis. The present invention also relates to a kit for the diagnosis of Crohn's disease and/or ulcerative colitis.

traducir

METHODS OF TREATING DISEASES

NºPublicación: US2020299378A1 24/09/2020

Solicitante:

BOEHRINGER INGELHEIM INT [DE]

JP_2019536756_A

Resumen de: US2020299378A1

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

traducir

METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO A GUT DYSBIOSIS

NºPublicación: US2020281991A1 10/09/2020

Solicitante:

CRESTOVO HOLDINGS LLC [US]

Resumen de: US2020281991A1

This application provides methods for determining or monitoring the pharmacokinetics (PK) and stable engraftment of live microbial therapeutics, in a subject, through a machine learning model. Disclosed herein is the monitoring and treating of a disorder related to a gut dysbiosis or inflammatory bowel disease in a subject.

traducir

METHOD OF DISCRIMINATING BETWEEN INFLAMMATORY BOWEL DISEASE AND GASTROINTESTINAL LYMPHOMA, DISCRIMINATION MARKER AND KIT

NºPublicación: WO2020179887A1 10/09/2020

Solicitante:

UNIV TOKYO [JP]

JP_2020143951_A

Resumen de: WO2020179887A1

The purpose of the present invention is to provide a method for discriminating between inflammatory bowel disease (IBD) and small-cell gastrointestinal lymphoma in carnivorous animals. A method for discriminating between IBD and small-cell gastrointestinal lymphoma in carnivorous animals is provided which involves a step for measuring the expression level in a test animal of an antimicrobial peptide selected from the group consisting of bactericidal/permeability-increasing protein (BPI), lactoferrin, secretory leukocyte peptidase inhibitor (SLPI), lysozyme and canine β-defensin.

traducir

ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI

NºPublicación: US2020271650A1 27/08/2020

Solicitante:

CEDARS-SINAI MEDICAL CENTER [US]

US_2019178890_A1

Resumen de: US2020271650A1

The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.

traducir

FECAL SAMPLE, BREATH SAMPLE COLLECTION AND ANALYSIS FOR TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020273540A1 27/08/2020

Solicitante:

VIVANTE HEALTH INC [US]

Resumen de: US2020273540A1

The invention is related to a system for treating irritable bowel syndrome, Crohn's disease, ulcerative colitis (collectively, inflammatory bowel disease, or “IBD”) by determining a number of indicators, including genetic markers, gene expression levels, levels of certain compounds in the gut or feces, hydrogen and/or methane levels, and concentrations of particular bacteria in the gut or feces, and correlating one or more such indicators with symptoms in test subjects with IBD; and correlating diet, drugs, supplements or other therapy, with alleviation of IBD symptoms. The correlations established in the test subjects are confirmed or refuted for individuals suffering IBD, and the treatments established as reducing symptoms are supported through messaging and compliance is verified by monitoring the indicators.

traducir

SYSTEM, COMPOSITION AND METHOD FOR THE DETECTION OF SPECTRAL BIOMARKERS OF A CONDITION AND PATTERNS FROM STOOL SAMPLES

NºPublicación: US2020264098A1 20/08/2020

Solicitante:

CLINICAI INC [US]

WO_2019094341_PA

Resumen de: US2020264098A1

A system, composition and method detect diseases using a method for identifying spectral biomarkers and patterns from stool samples. In one embodiment, the system, composition and method may provide a non-invasive method for detecting colorectal cancer and precancerous polyps comprises subjecting stool samples from cancerous and non-cancerous subjects to hyperspectral spectroscopy and wherein differences in spectra indicates cancer, or assesses risk of development thereof. The system, composition and method may also include a method for identifying spectral biomarkers and patterns from stool samples from cancerous, precancerous and inflammatory bowel disease subjects.

traducir

CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS

NºPublicación: US2020262907A1 20/08/2020

Solicitante:

AMGEN INC [US]
MEDIMMUNE LLC [US]

JP_2019508370_A

Resumen de: US2020262907A1

The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

traducir

METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS

NºPublicación: EP3693736A2 12/08/2020

Solicitante:

NOGRA PHARMA LTD [IE]

US_2020032264_A1

Resumen de: EP3693736A2

Methods of treating IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CCL20, IL8, or TNFα levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CCL20, IL8, or TNFα levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CCL20, IL8, or TNFα levels may correlated with IBD remission or decreases in CDAI score.

traducir

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES

NºPublicación: US2020246488A1 06/08/2020

Solicitante:

THE BROAD INSTITUTE INC [US]
MASSACHUSETTS GEN HOSPITAL [US]

WO_2019018410_PA

Resumen de: US2020246488A1

Embodiments disclosed herein provide methods for modulating intestinal epithelial cell integrity, migration, proliferation, differentiation, maintenance and/or function in which the expression of Cp1orf106 or its protein product are modulated such that the stability of the protein is altered. In certain example embodiments, increasing the stability or preventing a decrease in the stability of Cp1orf106 protein increases the overall integrity of the intestinal epithelium, thereby resulting in a decreased incidence of inflammatory disease. Increased integrity or stability of the epithelium may prevent invasion of migratory cells such as cancer cells.

traducir

IL6 GENE SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PREDICTING RISK OF DEVELOPING DRUG-INDUCED LEUKOPENIA AND METHOD FOR PREDICTING RISK OF LEUKOPENIA USING SAME

NºPublicación: WO2020153617A1 30/07/2020

Solicitante:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
SEOUL NAT UNIV HOSPITAL [KR]

KR_20200092864_A

Resumen de: WO2020153617A1

The present invention relates to a composition for predicting the risk of developing leukopenia comprising a single nucleotide polymorphism marker in an IL6 gene and a method for predicting the risk of developing leukopenia using same. As the single nucleotide polymorphism marker in an IL6 gene according to the present invention has a high correlation with the risk of developing leukopenia induced by drugs, in particular thiopurine-based drugs, patients with high susceptibility to leukopenia occurring during thiopurine-based drug treatment from leukemia, Crohn's disease, ulcerative colitis, or organ transplantation etc. can be effectively predicted or diagnosed by using the single nucleotide polymorphism marker at an early stage, and by administering a drug suitable for the patient through such prediction and diagnosis, it is possible to efficiently perform patient-specific treatment that can achieve an optimal treatment effect. Furthermore, the single nucleotide polymorphism marker according to the present invention can be utilized in drug development studies for the treatment of drug-induced leukopenia.

traducir

METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION

NºPublicación: US2020237801A1 30/07/2020

Solicitante:

NOGRA PHARMA LTD [IE]
CELGENE CORP [US]

WO_2017197180_A1

Resumen de: US2020237801A1

Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.

traducir

METHODS FOR MONITORING VEDOLIZUMAB TREATMENT

NºPublicación: US2020241006A1 30/07/2020

Solicitante:

PROMETHEUS BIOSCIENCES INC [US]

KR_20200069333_A

Resumen de: US2020241006A1

The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-α4β7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.

traducir

Microbial biomarker specific to irritable bowel syndromeIBS and method for predicting risk of irritable bowel syndrome using the same

NºPublicación: KR20200090135A 28/07/2020

Solicitante:

CHUNLAB INC [KR]

Resumen de: KR20200090135A

본 발명은 과민성 대장증후군(IBS)의 진단 또는 위험도 예측을 위한 바이오마커 및 상기 바이오마커를 이용한 IBS의 진단 또는 위험도 예측 방법을 제공한다. 또한 본 발명은 상기 바이오마커를 탐지하기 위한 조성물 및 상기 조성물을 포함하는 과민성 대장증후군의 진단 또는 위험도 예측용 키트를 제공한다. 본 발명이 제공하는 바이오마커는 장내 미생물을 속 또는 종 수준에서 동정함으로써 보다 정확도 높은 과민성 대장증후군의 진단 및 위험도 예측이 가능하다.

traducir

METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020231690A1 23/07/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

TW_201842191_A

Resumen de: US2020231690A1

The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

traducir

IRRITABLE BOWEL SYNDROME-SPECIFIC MICROBIAL BIOMARKER, AND METHOD FOR PREDICTING RISK OF IRRITABLE BOWEL SYNDROME BY USING SAME

NºPublicación: WO2020149719A2 23/07/2020

Solicitante:

CHUNLAB INC [KR]

Resumen de: WO2020149719A2

The present invention provides a biomarker for the diagnosis or risk prediction of irritable bowel syndrome (IBS), and a method for the diagnosis or risk prediction of IBS by using the biomarker. In addition, the present invention provides a composition for detecting the biomarker, and a kit for diagnosis or risk prediction of irritable bowel syndrome, comprising the composition. The biomarker provided in the present invention identifies intestinal microorganisms at the genus or species level, thereby enabling more accurate diagnosis or risk prediction of irritable bowel syndrome.

traducir

BLOOD-BASED SIGNATURES FOR DIAGNOSIS AND SUB-TYPING OF INFLAMMATORY BOWEL DISEASE SUBSETS

NºPublicación: WO2020142276A1 09/07/2020

Solicitante:

UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2020142276A1

This disclosure provides a method for analyzing peripheral blood leukocytes. In some embodiments, method may comprise: (a) labeling peripheral blood leukocytes isolated from a patient that has or is suspected of having inflammatory bowel disease (IBD) with a panel of distinguishably-labeled antibodies and (b) analyzing binding of the antibodies to the peripheral blood leukocytes. Kits for performing the method are also provided. Results from the analysis can be used to make a diagnosis of Crohn's disease or ulcerative colitis.

traducir

METHODS OF TREATING DISEASES

NºPublicación: EP3677597A1 08/07/2020

Solicitante:

BOEHRINGER INGELHEIM INT [DE]

US_2020299378_A1

Resumen de: EP3677597A1

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

traducir

SINGLE IMMUNOGLOBULIN INTERLEUKIN-1 RECEPTOR RELATED (SIGIRR) VARIANTS AND USES THEREOF

NºPublicación: CN111373053A 03/07/2020

Solicitante:

REGENERON PHARMA

KR_20200058435_A

Resumen de: CN111373053A

The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based onthe identification of such alterations in the nucleic acid molecules encoding SIGIRR.

traducir

METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2

NºPublicación: WO2020139748A1 02/07/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2020139748A1

Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein.

traducir

DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL INFLAMMATION

NºPublicación: US2020209261A1 02/07/2020

Solicitante:

BAYLOR COLLEGE MEDICINE [US]

WO_2018209318_A2

Resumen de: US2020209261A1

Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.

traducir

GP2 ISOFORMS AND THEIR USE IN AUTOANTIBODY CAPTURE

NºPublicación: US2020209258A1 02/07/2020

Solicitante:

GA GENERIC ASSAYS GMBH [DE]

Resumen de: US2020209258A1

The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).

traducir

Irritable bowel syndrome serum metabolism marker combination and diagnostic kit thereof

NºPublicación: CN111351870A 30/06/2020

Solicitante:

KMBGI TECH CO LTD

Resumen de: CN111351870A

The invention discloses an irritable bowel syndrome serum metabolism marker combination. The irritable bowel syndrome serum metabolism marker combination can be used for in vitro diagnosis of the irritable bowel syndrome and can assist a clinician in judging whether a patient suffers from the irritable bowel syndrome or not, and the metabolic markers are expected to be applied to treatment targetsof the irritable bowel syndrome, so that the treatment effect of a clinical patient is improved. The invention also discloses a diagnostic kit for irritable bowel syndrome. The kit is constructed onthe basis of the principle that abundance data is analyzed by a liquid chromatography-mass spectrometry metabonomics analysis method on serum samples of positive control and negative control. It is verified that the kit has a high detection rate and high accuracy, can comprehensively reflect the serum metabolism marker difference condition of patients with irritable bowel syndrome, can be used forearly discovery of irritable bowel syndrome, strives for time for patients, starts treatment as soon as possible, and improves the clinical treatment effect.

traducir

Antigen associated with inflammatory bowel disease

NºPublicación: CN111329994A 26/06/2020

Solicitante:

PHILOGEN SPA

ES_2743423_T3

Resumen de: CN111329994A

The invention provides specific binding members of ED-A isoforms that bind fibronectin. The specific binding members can be used for treatment, diagnosis, detection and/or photographic methods for inflammatory bowel disease (IBD), and/or used for delivering a molecule conjugated to the specific binding member to IBD tissue. The specific binding member provided by the invention can be conjugated, for example, to an immunosuppressive or anti-inflammatory molecule, such as interleukin-10.

traducir

Novel application of C60 and product activity detection method thereof

Nº publicación: CN111329882A 26/06/2020

Solicitante:

LI XINRONG

Resumen de: CN111329882A

The invention discloses a novel application of C60 and a product activity detection method thereof, and belongs to the field of functional products. The new application mainly relates to an application of C60 in preparation of anti-inflammatory products, beauty products and health products. The C60 (Carbon-60) achieves the anti-inflammatory and anti-inflammatory pain and pruritus effects by inhibiting human neutrophil secretion TNF-alpha and inhibiting human neutrophil migration; and the C60 acts on skin mucosa to generate a certain anti-inflammatory or beauty effect, and the C60 has a slightinhibition effect on human neutrophil phagocytic foreign matters. The C60 product has an obvious improvement effect on release, migration and phagocytosis related diseases of human neutrophil TNF-alpha such as intractable skin pruritus, colitis, pruritus caused by mosquito bites, external auditory canal pruritus related to earwax, hemorrhoids, head neuralgia, pain caused by herpes zoster, chronictendon injury, muscle fascia pain and/or arthralgia, has the effects of whitening and thinning the face, and can improve blood circulation.

traducir

Página1 de 3 nextPage por página

punteroimgVolver